Status:
COMPLETED
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis (RA)
Psoriatic Arthritis (PsA)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abata...
Eligibility Criteria
Inclusion
- Diagnosis of rheumatoid arthritis (RA) or psoriatic arthritis (PsA)
- Receiving treatment with abatacept
- Receiving treatment with non-targeted DMARD
- Receiving treatment with targeted DMARD
Exclusion
- Not applicable
Key Trial Info
Start Date :
June 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2025
Estimated Enrollment :
38396 Patients enrolled
Trial Details
Trial ID
NCT05421442
Start Date
June 13 2019
End Date
October 31 2025
Last Update
December 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Lawrenceville, New Jersey, United States, 08543